| Autor: |
Pamela L. Alebna, MD, MPH, Chin Yip Han, MD, Mathew Ambrosio, MS, Gwyneth Kong, MD, John W. Cyrus, BA, Kayla Harley, BA, Le Kang, PhD, Aeron M. Small, MD, MTR, Parag Chevli, MBBS, MS, Harpreet Bhatia, MD, MAS, Nicholas Chew, MD, Fadi N. Salloum, PhD, Dave L. Dixon, PharmD, Antonio Abbate, MD, PhD, Pradeep Natarajan, MD, MMSc, Michael D. Shapiro, DO, MCR, Anurag Mehta, MD |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
JACC: Advances, Vol 3, Iss 12, Pp 101409- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2772-963X |
| DOI: |
10.1016/j.jacadv.2024.101409 |
| Popis: |
Background: Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease. The relationship between Lp(a) and major adverse cardiovascular events (MACE) in the context of high-sensitivity C-reactive protein (hs-CRP) levels remains controversial due to conflicting results from previous studies. Objectives: This systematic review and meta-analysis aimed to clarify the association between Lp(a) and risk of MACE across different hs-CRP levels in both primary and secondary prevention settings. Methods: We performed a systematic review by searching MEDLINE (PubMed), Embase (Ovid), Cochrane CENTRAL (Wiley), and Web of Science (Clarivate) from their inception to February 2024. Eligible studies reported the association of Lp(a) with MACE stratified by hs-CRP level. Data extraction and quality assessment were systematically conducted. Meta-analyses used random-effects models to compute pooled HRs for individuals with low ( |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
